Skip to main content Skip to main navigation menu Skip to site footer
Confinia Cephalalgica

eISSN 3035-0670 | Official journal of the Italian Society for the Study of Headaches (SISC)

  • About the Journal
  • Publication Ethics
  • Editorial Board
  • Current
  • Archives
  • Copyright
  • Register
  • Login
  • Search
  • Contacts
  • News

Editor-in-Chief: Pierangelo Geppetti, Italy

0.5
CiteScore 2024
0.5
CiteScore 2024
Submit
an article
  1. Home /
  2. Search

Search

Advanced filters
Published After
Published Before

Search Results

##search.searchResults.foundPlural##
  • PO-22 | Impact of sleep disorders on anti-CGRP monoclonal antibodies treatment response in migraine: a cross-sectional study Costanza Sottani,1 Valerio Brunetti,1,2 Fabiana Cerulli,1 Claudia Garattini,4 Gianluca Avino,5 Paolo Calabresi,1,3 Catello Vollono1,4 | 1Università Cattolica del Sacro Cuore, Dipartimento di Neuroscienze, Rome; 2Stroke Unit, Fondazione Policlinico Agostino Gemelli IRCSS, Rome; 3UOC Neurologia, Fondazione Policlinico Agostino Gemelli IRCSS, Rome; 4UOC Neurofisiopatologia, Fondazione Policlinico Agostino Gemelli IRCSS, Rome; 5Unità di Neurologia, Ospedale Santo Stefano, Prato, Italy

    Società Italiana per lo Studio delle Cefalee (SISC)
    06-11-2025
    https://doi.org/10.4081/cc.2025.15844
    177
  • Prospective evaluation of aura during anti-calcitonin gene-related peptide monoclonal antibody therapy after 52 weeks of treatment

    Marina Romozzi, Andrea Burgalassi, Catello Vollono, Maria Albanese, Giulia Vigani, Francesco De Cesaris, Alberto Chiarugi, Paolo Calabresi, Luigi Francesco Iannone
    07-05-2024
    https://doi.org/10.4081/cc.2024.15762
    3803
    PDF: 592
  • Plasma CGRP but not PACAP-38 concentrations are associated with response to anti-CGRP monoclonal antibodies in migraine

    Elisa Rubino, Andrea Marcinnò, Silvia Boschi, Elisa Maria Piella, Alberto Mario Chiarandon, Fausto Roveta, Erica Gallo, Innocenzo Rainero
    26-11-2025
    https://doi.org/10.4081/cc.2025.15790
    492
    PDF: 128
  • PO-77 | Real-world evidence of Atogepant efficacy in patients unresponsive to anti-CGRP monoclonals Matteo Cortinovis, Marco Bolchini, Paola Zavarise, Giulia Campana, Giorgio Dalla Volta | Headache Center, Istituto Clinico Città di Brescia, Gruppo San Donato, Brescia, Italy

    Società Italiana per lo Studio delle Cefalee (SISC)
    06-11-2025
    https://doi.org/10.4081/cc.2025.15901
    306
  • Exploring the cortical effect of monoclonal antibodies against CGRP ligand: a pilot study of the cortical silent period in migraine

    Gabriele Sebastianelli, Giulia Rosaria Melis, Chiara Abagnale, Francesco Casillo, Cherubino Di Lorenzo, Mariano Serrao, Gianluca Coppola
    09-05-2025
    https://doi.org/10.4081/cc.2025.15778
    1545
    PDF: 333
  • Anti-CGRP monoclonal antibodies and migraine with aura: a narrative review

    Danilo Antonio Montisano, Marcella De Luca, Sara Giannoni, Giada Giuliani, Marilena Marcosano, Antonio Munafò, Daniele Pala, Federica Pes, Marina Romozzi, Gabriele Sebastianelli
    12-09-2025
    https://doi.org/10.4081/cc.2025.15789
    1038
    PDF: 508
  • PO-78 | No changes in blood pressure assessed with the 24-hour Holter monitoring in patients treated with anti-CGRP monoclonal antibodies: a prospective observational study (SAFHYPER) Flavia Lo Castro,1 Niccolò Bonini,2 Luigi Francesco Iannone,1,3 Alberto Boccalini,1 Daria Brovia,1 Luca Pani,1,3 Giuseppe Boriani,2,3 Simona Guerzoni1 | 1Digital and Predictive Medicine, Pharmacology and Clinical Metabolic Toxicology-Headache Center and Drug Abuse-Laboratory of Clinical Pharmacology and Pharmacogenomics, AOU Policlinico di Modena, Modena, Italy; 2Cardiology Division, AOU Policlinico di Modena, Modena, Italy; 3Department of Biomedical, Metabolic, and Neural Science, University of Modena and Reggio Emilia, Modena, Italy

    Società Italiana per lo Studio delle Cefalee (SISC)
    06-11-2025
    https://doi.org/10.4081/cc.2025.15902
    272
  • OC-09 | Atogepant in treatment-refractory chronic migraine: is a revision of current criteria for refractory migraine appropriate? Lorenzo Tartaglione, Marcello Silvestro, Ilaria Orologio, Marcella Marziani, Francesco Maurizio Chianese, Pasquale Sozio, Alessandro Tessitore, Gioacchino Tedeschi, Antonio Russo | Headache Center, Department of Advanced Medical and Surgical Sciences (DAMSS), University of Campania "Luigi Vanvitelli", Naples, Italy

    Società Italiana per lo Studio delle Cefalee (SISC)
    06-11-2025
    https://doi.org/10.4081/cc.2025.15806
    320
  • PO-21 | Evaluating the impact of anti-CGRP monoclonal antibodies on retinal features in migraine patients: a retrospective optical coherence tomography study Chiara Serafini,1 Massimo Cesareo,2 Alessio Martucci,2 Marco Lombardo,2 Vittoria Carla D’Agostino,1 Alessandro Stefani,3 Carlo Nucci,2 Nicola Biagio Mercuri,1,3 Maria Albanese1,3 | 1Regional Referral Headache Center, Neurology Unit, Tor Vergata University Hospital, Rome, Italy 2Ophthalmology Unit, Department of Experimental Medicine, University of Rome “Tor Vergata”, Rome; 3Department of Systems Medicine, University of Rome “Tor Vergata”, Rome, Italy

    Società Italiana per lo Studio delle Cefalee (SISC)
    06-11-2025
    https://doi.org/10.4081/cc.2025.15843
    230
  • OC-13 | Monoclonal antibodies targeting CGRP differently affect sleep and psychiatric comorbidities in reproductive and postmenopausal chronic migraine women Giulia Procopio, Letizia Curto, Antonia Di Chirico, Leonardo Troilo, Gabriele Siciliano, Filippo Baldacci, Sara Gori | Neurology Unit, Department of Clinical and Experimental Medicine, University of Pisa-AOUP, Pisa, Italy

    Società Italiana per lo Studio delle Cefalee (SISC)
    06-11-2025
    https://doi.org/10.4081/cc.2025.15810
    374
  • PO-86 | CGRP, VIP and PACAP plasmatic levels in migraine patients before and after anti-CGRP(R) monoclonal antibodies prophylaxis Alessia Bellotti,1 Davide Chiasserini,2 Alfredo Megaro,2 Daniela Fruttini,3 Pierluigi Navarra,4 Giuseppe Tringali,4 Paolo Calabresi,5 Lucilla Parnetti,1 Paola Sarchielli1 | 1Department of Medicine and Surgery, Section of Neurology, University of Perugia, Perugia, Italy; 2Department of Medicine and Surgery, Section of Physiology and Biochemistry, University of Perugia, Perugia, Italy; 3Department of Medicine and Surgery, Section of Internal Medicine, University of Perugia, Perugia, Italy; 4Department of Healthcare Surveillance and Bioethics, Section of Pharmacology, Catholic University Medical School, Fondazione Policlinico Universitario A. Gemelli-IRCCS, Rome, Italy; 5Department of Medicine and Surgery, Section of Neurology, Catholic University Medical School, Fondazione Policlinico Universitario A. Gemelli-IRCCS, Rome, Italy

    Societò Italiana per lo Studio delle Cefalee (SISC)
    06-11-2025
    https://doi.org/10.4081/cc.2025.15910
    255
  • PO-52 | Long-term efficacy of CGRP mAbs: new insights and current evidence Oreste Marsico,1 Marta Lioi,2 Rosario Iannacchero,3 Michele Trimboli3 | 1Department of Neuroscience, “Giovanni Paolo II” Hospital, Lamezia Terme, Catanzaro, Italy; 2Department of Neurology, Magna Graecia University, Catanzaro, Italy; 3Institute of Neurology, AOU Renato Dulbecco, Catanzaro, Italy

    Società Italiana per lo Studio delle Cefalee (SISC)
    06-11-2025
    https://doi.org/10.4081/cc.2025.15875
    131
  • PO-70 | A nomogram for the prediction of response to anti-CGRP mAbs: the CGRP score Marina Romozzi,1 Ammar Lokhandwala,2 Catello Vollono,1 David García-Azorín,3 Giulia Vigani,4 Francesco De Cesaris,4 Claudia Altamura,5 Fabrizio Vernieri,5 Paolo Calabresi,1 Sonia Di Tella,6 Luigi Francesco Iannone7 1Dipartimento Universitario di Neuroscienze, Università Cattolica del Sacro Cuore, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy; 2Drexel University, Philadelphia, PA, USA; 3Hospital Universitario del Río Hortega, Valladolid, Headache Unit, Department of Neurology, Valladolid, Spain; 4Section of Clinical Pharmacology and Oncology, Department of Health Sciences, University of Florence, Florence, Italy; 5 Neurologia, Dipartimento di Medicina e Chirurgia, Università Campus Bio-Medico di Roma, Rome, Italy; 6Dipartimento di Psicologia, Università Cattolica del Sacro Cuore, Milan, Italy; 7Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy

    Società Italiana per lo Studio delle Cefalee (SISC)
    06-11-2025
    https://doi.org/10.4081/cc.2025.15893
    193
  • Anti-CGRP monoclonal antibodies improve cognitive function in patients affected by chronic migraine complicated with medication overuse-headache

    Simona Guerzoni, Flavia Lo Castro, Carlo Baraldi, Daria Brovia, Fabio Tascedda, Veronica Rivi, Luca Pani
    07-05-2024
    https://doi.org/10.4081/cc.2024.15760
    3431
    PDF: 769
  • PO-43 | Eptinezumab in migraine patients unresponsive to prior subcutaneous CGRP(-R) monoclonal antibody treatment: a retrospective case series Elena Cresta, Irene Mattioli, Michele Di Pasquale, Alice Lanfranchi, Renata Rao, Alessandro Padovani | Neurology Unit and Headache Centre, Dipartimento di continuità di cura e fragilità, ASST Spedali Civili e Università degli studi di Brescia, Brescia, Italy

    Società Italiana per lo Studio delle Cefalee (SISC)
    06-11-2025
    https://doi.org/10.4081/cc.2025.15865
    237
  • PO-80 | Real-world effectiveness of atogepant for the preventive treatment of migraine in a cohort of multi -refractory patients: a single center study M. De Luca,1 L. Ferraù,1 A. Cafarchio,2 M.S. Adragna,1 M. Autunno1 | 1Unit of Neurology and Neuromuscular Diseases, Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy; 2Department of Medicine and Health Sciences “Vincenzo Tibero” DIMES, University of Molise, Campobasso, Italy

    Società Italiana per lo Studio delle Cefalee (SISC)
    06-11-2025
    https://doi.org/10.4081/cc.2025.15904
    242
  • PO-57 | Early treatment with atogepant improves sleep quality without sleep-related adverse events: a prospective observational study Alberto Boccalini,1 Luigi Francesco Iannone,1,2* Flavia Lo Castro,1 Daria Brovia,1 Marina Romozzi,3,4 Fabrizio Vernieri,5,6 Claudia Altamura,5,6 Simona Guerzoni1 | 1Digital and Predictive Medicine, Pharmacology and Clinical Metabolic Toxicology-Headache Center and Drug Abuse-Laboratory of Clinical Pharmacology and Pharmacogenomics, AOU Policlinico di Modena, Modena, Italy; 2Department of Biomedical, Metabolic, and Neural Science, University of Modena and Reggio Emilia, Modena, Italy; 3Dipartimento Universitario di Neuroscienze, Università Cattolica del Sacro Cuore, Rome, Italy; 4Neurologia, Dipartimento di neuroscienze, Organi di Senso e Torace, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy; 5Headache Unit, Fondazione Policlinico Universitario Campus Bio-Medico, Roma, Italy; 6Università Campus Bio-Medico di Roma, Italy

    Società Italiana per lo Studio delle Cefalee (SISC)
    06-11-2025
    https://doi.org/10.4081/cc.2025.15880
    179
  • PO-56 | The role of bilateral greater occipital nerve block in resistant chronic migraine with medication overuse Leonardo Troilo, Letizia Curto, Giulia Procopio, Antonia Di Chirico, Gabriele Siciliano, Sara Gori, Filippo Baldacci | Neurology Unit, Department of Clinical and Experimental Medicine, University of Pisa-AOUP, Pisa, Italy

    Società Italiana per lo Studio delle Cefalee (SISC)
    06-11-2025
    https://doi.org/10.4081/cc.2025.15879
    149
  • PO-19 | Unraveling the spectrum of migraine resistant to treatments: searching for novel biological PHEnotypes and theRApeutic approaches (SPHERA project) M. Giraudo,1,2 R. De Icco,1,2 G. Vaghi,1,2 V. Grillo,1,2 F. Bighiani,1,2 M. Corrado,2 A. Antoniazzi,1,2 F. Cammarota,1,2 B. Agostini,1,2 A. Solfrizzi,1,2 M. Allena,2 E. Guaschino,2 N. Ghiotto,2 R. Greco,2 C. Demartini,2 A. Zanaboni,1,2 M. Francavilla,1,2 S. Facchetti,1,2 G. Sances,2 C. Tassorelli1,2 | 1Department of Brain and Behavioral Sciences, University of Pavia; 2Headache Science and Neurorehabilitation Unit, IRCCS Mondino Foundation, Pavia, Italy

    Società Italiana per lo Studio delle Cefalee (SISC)
    06-11-2025
    https://doi.org/10.4081/cc.2025.15840
    219
  • Diaphragmatic small bowel disease in a patient with resistant migraine and medication overuse treated with galcanezumab

    Marilena Marcosano, Nicoletta Brunelli, Alessandro Alesina, Luisa Fofi, Claudia Altamura, Fabrizio Vernieri
    23-12-2024
    https://doi.org/10.4081/cc.2024.15768
    659
    PDF: 256
1 - 20 of 20 items

authors

FOR AUTHORS
  • SUBMIT YOUR PAPER
  • Guide for Authors
  • Benefits for Authors
  • How to write a scientific paper
  • How to write a Review article

reviewers

FOR REVIEWERS
  • Benefits for Reviewers
  • How to review

Categories

    • Contents

indexing

INDEXING
  • Scopus
  • OpenAlex
  • Analytics

Keywords

Confinia Cephalalgica

is an Open Access, peer-reviewed journal published by PAGEPress®, Pavia, Italy. All credits and honors to PKP for their OJS. eISSN 3035-0670 (Website continuously updated).

pISSN: 1122-0279
eISSN: 3035-0670

Info

  • About
  • Editorial Board
  • News
  • Advertising

Info Submission

  • Submission
  • Guidelines For Authors

Our App Is Free For Anyone!

Themes by Openjournaltheme.com

© PAGEPress 2008-2026    •    PAGEPress® is a registered trademark property of PAGEPress srl, Italy    •    VAT: IT02125780185    •    Privacy